after blood transfusions from HLA-homozygous donors to ical complication after allogeneic bone marrow transplantation related or unrelated recipients that were heterozygous for the Here we describe an unusual clinical course of a patient is described, who was given non-myeloablative remission reinwith AML, who developed acute and chronic GVHD after 
with only mild acute GVHD (cutaneous grade 1). From day 150 onwards, CsA was gradually tapered over 4 weeks, without clinical evidence of acute GVHD. On day 184, a bone Introduction marrow relapse of AML was diagnosed. At this time, 20% of peripheral blood erythrocytes were blood group B, ie of recepIn 1966, Billingham defined three basic requirements for grafttor origin. Bone marrow karyotyping now revealed 47, XX, +8, versus-host disease (GVHD) with almost visionary accuracy.
inv(16)(p13q22). The patient underwent remission reinduction Research in the following decades confirmed that GVHD with high-dose Ara-C i.v. on days 191-195, and was readmitdevelops when sufficient numbers of immunocompetent ted on day 236 with low-grade fever, a diffuse pruritic maculdonor T lymphocytes are transferred (condition 1) into a genopapular rash (Ͼ50% of body surface), gastrointestinal disetically disparate host (condition 2), that is immunoincompetturbance with nausea, vomiting and mild diarrhea, and ent and not capable of rejecting the allogeneic T cells elevated liver enzymes characteristic of cholestatic hepatitis. (condition 3). 1 These requirements are typically fulfilled in the The blood group had reverted to A, and the marrow karyotype clinical setting of non-T cell-depleted allogeneic bone marrow was now 46, XX (5/5 mitoses). CMV isolation from throat, transplantation (allo-BMT) or allogeneic peripheral blood prourine or peripheral blood, HbsAg assay, and stool culture all genitor cell transplantation. Less commonly is GVHD yielded no causative pathogens. A tentative diagnosis of acute observed after solid organ (eg small bowel) transplantation or GVHD grade 3 was made. 6 A liver biopsy performed on day after transfusion of blood products to immunodeficient or 237, was compatible with (but not diagnostic of) hepatic immunosuppressed recipients (for review see Refs 2 and 3). It GVHD (not shown). On day 239 a skin biopsy was performed, occurs only very rarely in immunocompetent patients, usually which confirmed the clinical diagnosis of acute GVHD, with a typical dermal mononuclear perivascular infiltrate and focal destruction of keratinocytes (Figure 2) , and with strongly HLA-DR positive keratinocytes and numerous CD1a-positive Lang- extracted from this skin biopsy, based on differences in these loci between donor and recipient. Donor and recipient alleles were found, but none of third party origin, excluding transfusion-associated GVHD ( Figure 3 ). CsA was restarted on day This unusual occurrence of acute GVHD led us to consider alternative sources of alloreactive T cells, eg the 10 units of 246 because of deterioration of the serum liver enzymes. From then onwards, the skin eruption became desquamating, and leukocyte-depleted packed cells, and the platelet concentrates from four single donors administered between day 190 and diarrhea and markers of hepatocellular necrosis improved, with protracted biochemical cholestasis, reflecting transition day 230. All of these had been irradiated prophylactically with 1500 cGy. This procedure reduces the number of viable and to chronic hepatic GVHD. The serum level of TNF-␣ on day 194 (during remission reinduction) and on day 236 (at the proliferation-competent T cells drastically, but does not absolutely rule out the possibility of transfusion-associated time of acute GVHD) was increased above normal, with increased serum concentrations of sIL2-R and of IL-6 on day GVHD. 7, 8 However, this possibility is sufficiently excluded by the favorable evolution after initiation of CsA, the absence of 236 as well (Table 1) . Forty-eight months after allo-BMT (as of May 1997), the patient enjoys an excellent performance persistent pancytopenia or slow hematopoietic recovery after chemotherapy, and the absence of third party STR alleles in status in continuing third complete remission. She has been off CsA since day 930 and has limited cutaneous and hepatic the day 239 skin biopsy. What apparently happened therefore, is that grafted donor chronic GVHD.
T cells recovered from reinduction chemotherapy more rapidly than the leukemic clone. Not being held in check any longer by CsA, they could now become activated by host Discussion alloantigens, multiply in number, and induce GVHD, mimicking the effect of an add-back of donor T lymphocytes.
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Having undergone allo-BMT, the index patient was predictably at risk for the development of GVHD. Yet the develBesides lack of immunosuppression, increased levels of proinflammatory cytokines, eg TNF-␣ or IL-6, may also have conopment of acute GVHD around day 230 was quite unexpected, given the previously uncomplicated course including tributed to GVHD by critically determining the threshold as well as the extent of acute GVHD. 2, 3 In the patient, serum tapering of CsA. The skin biopsy (Figure 2) , and the response to CsA, however, leave little uncertainty about the diagnosis TNF-␣ was slightly increased above normal on day 194 (ie the third day of remission reinduction therapy) and on day of acute GVHD. 236 (at the time of acute GVHD) and remained elevated until at least day 439 after allo-BMT, IL-6 was also increased in serum samples obtained on day 236 and day 439 (Table 1) , consistent with reported data for acute and chronic GVHD. [14] [15] [16] The increase in serum TNF-␣ and IL-6 levels is only modest, but uniform compared with shortly after allo-BMT, all samples being measured within a single experiment and using a very reliable commercial assay. As the Billingham criteria fail to explain the development of GVHD at this particular time 1 and as suggested by the 'cytokine storm' model of GVHD, 2,3 one could hypothesize that a rise in TNF-␣ and IL-6 was triggered by remission reinduction chemotherapy. These increases may subsequently have affected the threshold for developing GVHD. Additional data points between reinduction chemotherapy and development of acute GVHD would be required better to support this hypothesis. Unfortunately, these cannot be obtained due to lack of more frozen serum samples from this time.
Alternatively, the presence of circulating donor erythrocytes at relapse, may suggest the existence of mixed donor-host chimerism, which could have maintained donor-host tolerance. By eradication of residual host hematopoiesis and establishing full donor chimerism, high-dose Ara-C may have broken this tolerance, resulting in development of GVHD and GVL effect 7 months after transplantation. Unfortunately, no studies addressing chimerism were performed between allo-BMT and relapse. 17, 18 The continuing complete remission until 48 months after allo-BMT (as of May 1997), without additional chemotherapy, suggests that the acute and chronic GVHD were associated and the development of acute GVHD. 3 Finally, continuing third complete remission of more than 41 months duration to Table 1 Serum levels of sIL-2R, IL-6 and of TNF-␣ at several time date, was obtained in this poor-risk patient. This suggests that, points after allo-BMT a besides reducing the tumor load through pharmacological mechanisms, the non-myeloablative chemotherapy created a
Day relative SIL-2R IL-6 TNF-␣ window of opportunity for GVHD and a strong GVL effect.
to BMT (pg/ml) (pg/ml) (pg/ml)
Non-myeloablative therapy may thus still be of potential use in the treatment of AML relapsing after allo-BMT. This 
